Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Seaport TherapeuticsSPTX -0.99%11 3-1 Month Momentum % is 32.47% as of Aug. 19, 2026. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,386 Biotechnology companies, Seaport Therapeutics ranks better than 89.97% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), Seaport Therapeutics's 3-1 Month Momentum % is 32.47%.
The industry rank for Seaport Therapeutics's 3-1 Month Momentum % or its related term are showing as below:
SPTX's 3-1 Month Momentum % is ranked better than 89.97% of 1386
companies
in the Biotechnology industry
Industry Median: -6.185
vs SPTX: 32.47
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Seaport Therapeutics 3-1 Month Momentum % Related Terms
SPTX vs SVRA, DRTS, FBRX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Seaport Therapeutics's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seaport Therapeutics 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Seaport Therapeutics's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Seaport Therapeutics (SPTX) has a 3-1 Month Momentum % of 32.47% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Seaport Therapeutics and its competitors. According to the industry distribution chart, Seaport Therapeutics ranks #139 out of 1386 companies in the Biotechnology industry, placing it in the top 10%.
Is Seaport Therapeutics' 3-1 Month Momentum % too high?
Seaport Therapeutics' current 3-1 Month Momentum % is 32.47%. Based on the distribution chart, Seaport Therapeutics ranks #139 out of 1386 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' 3-1 Month Momentum % compare to SVRA and DRTS?
According to the Biotechnology industry distribution chart, Seaport Therapeutics ranks #139 out of 1386 companies for 3-1 Month Momentum %. This places Seaport Therapeutics in the top 10% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current 3-1 Month Momentum % is 32.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current 3-1 Month Momentum % of 32.47%. The current 3-1 Month Momentum % is 32.47%. Seaport Therapeutics' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current 3-1 Month Momentum % is 32.47% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score
Get the complete analysis for SPTX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPTX has been successfully added to your 
